CN107072947A - 用于吸入的干粉制剂 - Google Patents

用于吸入的干粉制剂 Download PDF

Info

Publication number
CN107072947A
CN107072947A CN201580052364.7A CN201580052364A CN107072947A CN 107072947 A CN107072947 A CN 107072947A CN 201580052364 A CN201580052364 A CN 201580052364A CN 107072947 A CN107072947 A CN 107072947A
Authority
CN
China
Prior art keywords
acetylsalicylic acid
particles
dry powder
dry
stage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580052364.7A
Other languages
English (en)
Chinese (zh)
Inventor
K.雅迪迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Victora
Original Assignee
Otitopic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55218356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107072947(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otitopic Inc filed Critical Otitopic Inc
Priority to CN202310193558.5A priority Critical patent/CN116687887A/zh
Publication of CN107072947A publication Critical patent/CN107072947A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201580052364.7A 2014-07-31 2015-07-31 用于吸入的干粉制剂 Pending CN107072947A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310193558.5A CN116687887A (zh) 2014-07-31 2015-07-31 用于吸入的干粉制剂

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031811P 2014-07-31 2014-07-31
US62/031,811 2014-07-31
PCT/US2015/043128 WO2016019253A1 (en) 2014-07-31 2015-07-31 Dry powder formulations for inhalation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310193558.5A Division CN116687887A (zh) 2014-07-31 2015-07-31 用于吸入的干粉制剂

Publications (1)

Publication Number Publication Date
CN107072947A true CN107072947A (zh) 2017-08-18

Family

ID=55218356

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580052364.7A Pending CN107072947A (zh) 2014-07-31 2015-07-31 用于吸入的干粉制剂
CN202310193558.5A Pending CN116687887A (zh) 2014-07-31 2015-07-31 用于吸入的干粉制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310193558.5A Pending CN116687887A (zh) 2014-07-31 2015-07-31 用于吸入的干粉制剂

Country Status (10)

Country Link
EP (2) EP4218734A1 (https=)
JP (1) JP6850524B2 (https=)
KR (2) KR102666667B1 (https=)
CN (2) CN107072947A (https=)
AU (2) AU2015296142A1 (https=)
CA (1) CA2991760C (https=)
DK (1) DK3179986T3 (https=)
ES (1) ES2942297T3 (https=)
PL (1) PL3179986T3 (https=)
WO (1) WO2016019253A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315363A (zh) * 2017-09-22 2020-06-19 欧缇托匹克公司 含有硬脂酸镁的干粉组合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176552A1 (en) 2015-04-30 2016-11-03 Otitopic Inc. Dry power formulations for inhalation
US10568894B2 (en) 2016-06-03 2020-02-25 Otitopic Inc. Dry powder formulations for inhalation
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
EP4311566A1 (en) 2022-07-28 2024-01-31 Vectura Inc. An inhaler comprising a retention element

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1658837A (zh) * 2002-04-13 2005-08-24 葛兰素集团有限公司 干粉吸入组合物
US20100258118A1 (en) * 2006-11-03 2010-10-14 Vectura Limited Inhaler devices and bespoke pharmaceutical compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
ES2237767T3 (es) 1995-04-14 2005-08-01 Nektar Therapeutics Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
MX9707862A (es) 1995-04-14 1997-11-29 Glaxo Wellcome Inc Inhalador de dosis medida para el propionato de fluticasona.
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
EP1013269A4 (en) * 1997-06-06 2002-02-20 Shionogi & Co IMPROVEMENT OF A DRUG ADMINISTRATION SYSTEM
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
CN1169520C (zh) 1997-09-29 2004-10-06 耐科塔医药公司 多孔微粒及其使用方法
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
WO2000000215A1 (en) 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
US7871598B1 (en) * 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
PT1296651E (pt) * 2000-06-27 2008-02-12 Vectura Ltd Método para fazer partículas para serem usadas numa composição farmacêutica
CA2465675C (en) 2001-11-20 2008-06-10 Advanced Inhalation Research, Inc. Improved particulate compositions for pulmonary delivery
WO2004030659A1 (en) * 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
WO2005115341A2 (en) 2004-05-27 2005-12-08 Advanced Bionutrition Corporation Microparticles for oral delivery
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
WO2006105167A2 (en) 2005-03-28 2006-10-05 Pericor Therapeutics, Inc. Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
WO2009026434A1 (en) 2007-08-21 2009-02-26 Alkermes, Inc. Pulmonary pharmaceutical formulations
NO2252275T3 (https=) 2008-02-13 2018-04-28
CA2759109A1 (en) * 2009-04-24 2010-10-28 Iceutica Pty Ltd A solid dosage form of ciprofloxacin having small particle size and improved powder handling characteristics
GB201102237D0 (en) 2011-02-09 2011-03-23 Kuecept Ltd Particle formulation
US9216527B2 (en) 2012-02-09 2015-12-22 G & W Electric Company Solid-dielectric switch including a molded viewing window
EP2819645A2 (en) * 2012-02-28 2015-01-07 Iceutica Holdings Inc. Bvi Inhalable pharmaceutical compositions
US9757395B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
HK1218720A1 (zh) 2013-04-30 2017-03-10 欧缇托匹克公司 干粉制剂及使用方法
ES2922206T3 (es) 2014-02-20 2022-09-09 Otitopic Inc Formulaciones de polvo seco para la inhalación

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1658837A (zh) * 2002-04-13 2005-08-24 葛兰素集团有限公司 干粉吸入组合物
US20100258118A1 (en) * 2006-11-03 2010-10-14 Vectura Limited Inhaler devices and bespoke pharmaceutical compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111315363A (zh) * 2017-09-22 2020-06-19 欧缇托匹克公司 含有硬脂酸镁的干粉组合物
CN111315363B (zh) * 2017-09-22 2022-10-11 奥迪托皮克股份有限公司 含有硬脂酸镁的干粉组合物
US12508227B2 (en) 2017-09-22 2025-12-30 Aspeya US Inc. Dry powder compositions with magnesium stearate

Also Published As

Publication number Publication date
CA2991760C (en) 2025-05-06
PL3179986T3 (pl) 2023-06-26
CA2991760A1 (en) 2016-02-04
KR20230119032A (ko) 2023-08-14
AU2020203437A1 (en) 2020-06-11
KR20170039255A (ko) 2017-04-10
KR102603897B1 (ko) 2023-11-20
WO2016019253A1 (en) 2016-02-04
WO2016019253A9 (en) 2016-05-12
EP3179986A4 (en) 2018-02-07
EP3179986A1 (en) 2017-06-21
DK3179986T3 (da) 2023-05-01
ES2942297T3 (es) 2023-05-31
AU2015296142A1 (en) 2017-02-23
EP4218734A1 (en) 2023-08-02
JP2017523189A (ja) 2017-08-17
AU2020203437B2 (en) 2020-09-17
CN116687887A (zh) 2023-09-05
EP3179986B1 (en) 2023-03-15
JP6850524B2 (ja) 2021-03-31
KR102666667B1 (ko) 2024-05-17

Similar Documents

Publication Publication Date Title
JP6701086B2 (ja) 吸入用の乾燥粉末製剤
US12343425B2 (en) Dry powder formulations for inhalation
AU2020203437B2 (en) Dry powder formulations for inhalation
US12144820B2 (en) Dry powder formulations for inhalation
HK1240081A1 (en) Dry powder formulations for inhalation
HK1240081B (en) Dry powder formulations for inhalation
HK1232442B (en) Dry powder formulations for inhalation
HK1232442A1 (en) Dry powder formulations for inhalation

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: OTITOPIC Inc.

Address before: California, USA

Applicant before: OTITOPIC Inc.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230110

Address after: Connecticut USA

Applicant after: Victora

Address before: California, USA

Applicant before: OTITOPIC Inc.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170818